Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | PRF1 | P14222 | 1/20 | 0.48 |
| ▸ | SNCA | P37840 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 2/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2251594 | 0.79 | HDAC1 (0.54) | HDAC6SNCANQO2MEN1TP53 | |
| SCHEMBL2019176 | 0.78 | PRF1 (0.58) | HDAC6PRF1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL10331340 | 0.78 | PRF1 (0.46) | HDAC6PRF1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5420514 | 0.78 | RAB9A (0.58) | HDAC6PRF1ALDH1A1HPGDMAPK13 | |
| SCHEMBL2357473 | 0.77 | PRF1 (0.49) | PRF1SNCAALDH1A1SMN1; SMN2MAPT | |
| Lithium Ion SCHEMBL5420511 | 0.76 | HSD17B1 (0.48) | HDAC6PRF1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL14189571 | 0.75 | HSD17B1 (0.50) | SNCAALDH1A1SMN1; SMN2HSD17B1HSD17B2 | |
| SCHEMBL10626283 | 0.75 | ALDH1A1 (0.64) | ALDH1A1HPGDSMN1; SMN2PDK2ERN1 | |
| SCHEMBL2778388 | 0.75 | SNCA (0.61) | SNCAALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL6606973 | 0.74 | ALDH1A1 (0.53) | ALDH1A1HPGDSMN1; SMN2ERN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113983-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| US-20080113983-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| US-20080113983-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| US-20070249588-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| EP-1699801-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005061510-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249588-A1 | Nicotinic Acetylcholine Receptor Ligands | CHRNA1, CHRNB1, CHRNA2 | HDAC6 1738/4885PRF1 4755/4885SNCA 1622/4885 |
| US-20080113983-A1 | Nicotinic Acetylcholine Receptor Ligands | CHRNA1, CHRNA2, CHRNB1 | HDAC6 1608/4885PRF1 4791/4885SNCA 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.